The reiteration of the 'Perform' rating and maintenance of the $25 price target by Oppenheimer suggests a neutral outlook on ACADIA Pharmaceuticals' stock in the short term. This analysis is based on the current market performance and the analyst's expectations, indicating no significant changes or updates that could drastically affect the stock's performance. Therefore, the impact on the stock price is likely to be neutral.